
    
      This study is a randomized, double-blind, double-dummy, crossover clinical trial which will
      consist of 5 study visits and will last up to 3 weeks.

      Fifteen children 12-17 years of age with asthma and EIB, regardless of current asthma therapy
      will be eligible for this trial.
    
  